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Up-regulation of glomerular COX-2 by angiotensin II: Role of
reactive oxygen species.
Background. Prostaglandins such as prostaglandin E2
(PGE2) and prostaglandin I2 (PGI2) counteract the angiotensin
II (Ang II)–induced vasoconstriction in the glomerular mi-
crocirculation. We have shown that Ang II promotes mesan-
gial cell hypertrophy via reactive oxygen species (ROS),
which originate from nicotinamide adenine dinucleotide phos-
phate and its reduced form (NADH/NADPH) oxidase. It has
been reported that conditions associated with activation of
the renin-angiotensin system result in increased glomerular
cyclooxygenase-2 (COX-2) expression and activity.
Methods. We designed studies to determine (1) whether Ang
II induces COX-2 in the glomerulus in vivo in the glomerulus
as well as in vitro in mesangial cells, (2) whether ROS orig-
inated from Ang II are involved, and (3) whether COX-2–
derived prostaglandins modulate the growth promoting effects
of Ang II in mesangial cells. Rats were infused with Ang II
(0.7 mg/kg/day) for 5 days and glomerular COX-2 expression
and activity assessed in isolated glomeruli.
Results. Ang II increased glomerular PGE2 production
(100%) accompanied by a concomitant increase in glomeru-
lar COX-2 expression at the mRNA (1.7-fold) and protein
level (sixfold). In mesangial cells, Ang II significantly in-
creased mesangial cell PGE2 (200%) and PGI2 (100%) pro-
duction as well as COX-2 mRNA that was prevented by
the angiotensin type 1 (AT1) receptor blocker irbesartan and
the COX-2 inhibitor NS-398. The NADPH oxidase inhibitor
diphenyleneiodonium (DPI), the ROS scavenger tiron as well as
catalase, inhibited Ang II–induced PGE2 production suggesting
that Ang II–induced ROS mediate COX-2 up-regulation. Strik-
ingly, COX-2 inhibition as well as blockade of the type 1 PGE2
receptor (EP1) prevented Ang II–induced mesangial cell hy-
pertrophy suggesting that COX-2–derived prostaglandins, and
specifically PGE2, importantly contribute to the growth pro-
moting effects of Ang II.
Conclusion. These studies suggest that blockade of specific
PGE2 receptors may be a novel strategy to modulate the patho-
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logic effects of COX-2–derived prostaglandins without simul-
taneously affecting protective vasodilatory mechanisms.
The countervailing interaction between angiotensin
II (Ang II) and prostaglandins plays a critical role in
the modulation of the renal microcirculation [1, 2].
Prostaglandins are produced in large amounts in the
glomerulus in response to a variety of stimuli, includ-
ing vasoactive agents such as Ang II [3–5], growth factors
[6], and proinflammatory cytokines [7]. Prostaglandin E2
(PGE2) is quantitatively the major prostaglandin pro-
duced in the kidney and it has been shown to have both
vasoconstrictory and vasodilatory actions on the renal
microcirculation [8, 9]. Other prostaglandins produced
in the kidney include prostaglandin I2 (PGI2) that has
predominant vasodilatory effects and thomboxane A2
(TxA2), a vasoconstrictory prostanoid [10].
Ang II and prostaglandins have important nonhemo-
dynamic effects that modulate the glomerular response to
injury. Ang II promotes mesangial cell hypertrophy and
proliferation [11–13] and increases extracellular matrix
deposition [14]. We have shown that in mesangial cells
these actions of Ang II are dependent to a great extent
upon the activation of protein kinase C (PKC) and nicoti-
namide adenine dinucleotide phosphate and its reduced
form (NADH/NADPH) oxidase which results in the gen-
eration of reactive oxygen species (ROS) and the ac-
tivation of mitogen-activated protein kinases (MAPKs)
[11]. PGE2 has been reported to modulate mesangial cell
proliferation in response to interleukin (IL)-1 [15] and
platelet-derived growth factor (PDGF) [16] and to re-
duce extracellular matrix expression [17]; however, other
studies have shown the opposite, namely that PGE2 me-
diates mesangial cell proliferation [18]. PGI2 has been
shown to inhibit while TxA2 promotes mesangial cell
proliferation[19–21].
Two enzymes are rate limiting in the synthesis of
prostaglandins: phospholipase A2 (PLA2), which cat-
alyzes the release of arachidonic acid from phospholipids
in cell membranes, and cyclooxygenase (COX), which
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catalyzes the conversion of arachidonic acid to PGG2 and
to PGH2 [22]. Two forms of COX have been identified,
COX-1 and COX-2. COX-1 is constitutively expressed
in most cell types [23, 24]. COX-2 is induced in re-
sponse to a variety of stimuli, including cytokines [7] and
growth factors [25, 26]. However, some of the pathways
involved in the glomerular synthesis of prostaglandins
via COX-2 as well the biologic consequences of glomeru-
lar prostaglandins synthesis remain poorly understood.
In combined in vivo and in vitro studies we tested the
hypothesis that Ang II modulates the expression and ac-
tivity of glomerular COX-2 and that in return prostanoids
derived from COX-2 modulate Ang II actions. In the in
vitro studies we focused on mesangial cells because of
the critical role of the glomerular mesangium in modu-
lating the glomerular microcirculation in response to va-
soactive agents. Furthermore, the same vasoactive agents
promote mesangial cell hypertrophy and proliferation,
as well as increased matrix production [27]. Herein, we
demonstrate that Ang II induces glomerular COX-2 ex-
pression and activity in vivo as well as in vitro in cultured
mesangial cells. These effects were found to be depen-
dent on Ang II–mediated ROS generation and MAPKs
activation. We also demonstrate, for the first time, that
COX-2–derived prostaglandins mediate in large part the
growth promoting effects of Ang II in mesangial cells.
METHODS
In vivo studies
Six-week-old Sprague-Dawley male rats were pur-
chased from Harlan (Indianapolis, IN, USA) and main-
tained under controlled conditions of light, temperature,
and humidity. Rats were divided in two groups: (1) con-
trol (N = 9), implanted with vehicle and (2) Ang II
(N = 9), infused with Ang II via osmotic minipump
at 0.7 mg/kg/day for 5 days. Minipumps (Alzet model
1007D; Alzet, Cupertino, CA, USA) were implanted in
the midscapular region under anesthesia with a cock-
tail of ketamine (45 mg/kg intraperitoneally), xylazine (8
mg/kg intraperitoneally), and acepromazine (1.5 mg/kg
intraperitoneally). Rats were sacrificed on day 5 and
kidney tissue saved for immunohistochemistry. Blood
pressure was measured before sacrifice by the tail-cuff
method. In addition glomeruli were isolated by sieving
as described [28] and used for reverse transcription-
polymerase chain reaction (RT-PCR), Western blot, and
PGE2 measurements.
In separate experiments, rats were divided into three
groups: (1) Control (N = 6), (2) Ang II (N = 6), infused
with Ang II via osmotic minipump at 0.7 mg/kg/day for
5 days and injected with the specific COX-2 inhibitor NS-
398 (1.5 mg/kg subcutaneously) 12 hours and 1 hour prior
to sacrifice. Rats were sacrificed on day 5, and glomeruli
isolated for PGE2 measurements.
Glomerular PGE2 measurements. Isolated glomeruli
from the two experimental groups were incubated in
RPMI 1640 with arachidonic acid 10−5 mol/L at 37◦C
for 1 hour with and without the COX-2 inhibitors NS-398
(10−7 mol/L), nimesulide (10−6 mol/L), or the nonspecific
COX inhibitor indomethacin (10−5 mol/L). At the end
of this incubation, the glomeruli were centrifuged, and
protein assayed. PGE2 was measured in the supernatant
by enzyme immunoassay (EIA) (Cayman, Ann Arbor,
MI, USA) and factored by glomerular protein content as
measured by the Bio-Rad method (Hercules, CA, USA).
Western blot. After isolation, glomeruli were homog-
enized and protein separated on 6% sodium dodecyl
sulfate (SDS) gels under reducing conditions and trans-
ferred to a nitrocellulose membrane (Hybond ECL)
(Amersham Biosciences Corp., Piscataway, NJ, USA).
The blots were incubated overnight with rabbit an-
timurine polyclonal antibody to COX-2 (Cayman; cat-
alogue number 160126), rabbit monoclonal antibody to
COX-1 (Cayman; catalogue number 160110), or actin
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). After
washing the blots were incubated with goat antirabbit an-
tibody (Santa Cruz Biotechnology) for 1 hour at a 1:2000
dilution and the signal detected by luminol chemilumi-
nescence.
Cox mRNA expression. COX-1 and COX-2 mRNA
expression in whole glomeruli was determined by RT-
PCR. Total RNA was isolated by lysing the glomeruli
in Trizol reagent (Life Technologies, Philadelphia, PA,
USA) and by precipitation in isopropyl alcohol. A
5 lg aliquot of total RNA was used for cDNA
synthesis with the Superscript Preamplification Sys-
tem (Life Technologies). An aliquot of cDNA was
amplified using Taq polymerase in the presence of
sense and antisense primers for rat COX-2: forward
5′-CAT TCT TTG CCC AGC ACT TCA C-3′, reverse 5′-
GAC CAG GCA CCA GAC CAA AGA C-3′; rat COX-
1: forward 5′-GTG AGC TAC TAT ACT CGC ATT C-3′,
reverse 5′-GCC AAA CCT CTT TCG GTA TTC-3′; and
glyderaldehyde-3-phosphate dehydrogenase (GAPDH);
forward 5′-CCT TCA CTA CAT GGT CTA CAT G-3′,
reverse 5′-GTT GAG CTC AGG GAT GAC CTT-3′.
Immunohistochemistry. Rats were sacrificed by
decapitation, kidneys harvested and fixed in 10%
paraformaldehyde. For antigen retrieval, slides were im-
mersed in target retrieval solution (DakoCytomation,
Carpinteria, CA, USA) for 30 minutes at 90◦C. COX-
2 immunoreactivity was localized with polyclonal rabbit
antimurine COX-2 antibody (Cayman),polyclonal rab-
bit antimurine COX-1 antibody (Cayman) or polyclonal
smooth muscle actin (Santa Cruz Biotechnology). As sec-
ondary antibodies we used goat antirabbit IgG (Santa
Cruz Biotechnology). The first antibody was localized
using Vectastain ABC-Elite (Vector, Burlingame, CA,
USA) with either diaminobenzidine (DAB) or alkaline
phosphatase as chromogen.
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Fig. 1. Angiotensin II (Ang II) infu-
sion increases glomerular production of
prostaglandin E2 (PGE2) that is inhibited
by two different cyclooxygenase (COX-2)
inhibitors as well as by indomethacin (Indo).
Results are expressed as mean ± SEM
(N = 6). ∗P < 0.05 compared to all other
conditions.
In situ hybridization
In situ hybridization studies were performed in kidneys
from control and Ang II–infused rats. For COX-2 probe
preparation, a plasmid containing the COX-2 cDNA
(Cayman) was used to generate sense and antisense ri-
boprobes using a digoxigenin (DIG) RNA labeling kit
(Boehinger-Mannheim, Indianapolis, IN, USA) accord-
ing to the manufacturer’s protocol. Prior to probe hy-
bridization, tissue was formalin-fixed and embedded in
paraffin and sectioned under RNAse-free conditions at
4 lm.
In vitro studies
Primary mesangial cell cultures were prepared from
male Sprague-Dawley rats as previously described [28,
29]. Cells were grown in RPMI 1640 media (Gibco,
Grand Island, NY, USA) supplemented with 17% heat-
inactivated fetal calf serum (FCS) (Hyclone Laborato-
ries, Logan, UT, USA).
Mesangial cells were made quiescent in RPMI
1640/0.5% FCS for 72 hours and exposed to Ang II
(10−5 to 10−9 mol/L) for 24 hours with and without the
specific COX-2 inhibitor NS-398 (10−7 mol/L), the non-
specific COX inhibitor indomethacin (10−5 mol/L), the
NADPH oxidase inhibitor dyphenilene iodinium (DPI)
(10−5 mol/L), the ROS scavenger Tiron (5 × 10−3 mol/L),
the angiotensin type 1 (AT1) receptor blocker irbesar-
tan (10−6 mol/L) or the MAPK-1 inhibitor PD98059
(10−6 mol/L). At the end of the incubation period me-
dia was collected and saved for prostaglandin determina-
tions. PGE2, 6-keto-PGF1a , the stable PGI2 metabolite,
and TxB2, the stable TxA2 metabolite, were measured
by EIA (Cayman), factored for cell protein content, and
expressed as ng/mg protein.
In separate experiments we measured COX-2 and
COX-1 mRNA expression by RT-PCR in mesangial cells
exposed to Ang II (10−7 mol/L) for 1 hour with and with-
out the NADPH oxidase inhibitor DPI.
3H-leucine incorporation. Mesangial cell protein syn-
thesis was measured by 3H-leucine incorporation as
previously described [11] and used as an index of mesan-
gial cell hypertrophy. Mesangial cells were grown in
6-well dishes, made quiescent in RPMI 1640/0.5% FCS
for 72 hours. Mesangial cells were then incubated for
48 hours with Ang II (10−7 mol/L) with and without the
specific COX-2 inhibitors NS-398 (10−6 to 10−7 mol/L)
or nimesulide (10−6 to 10−7 mol/L), the nonspecific
COX inhibitor indomethacin (10−5 mol/L), or the specific
COX-1 inhibitor SC-560 (10−7 mol/L). Six hours before
harvesting, mesangial cells were pulsed with 3H-leucine
2 lCi/mL. After solubilization with SDS, duplicate ali-
quots were counted in a scintillation counter and the re-
sults were expressed as percent of change vs. control.
RESULTS
In vivo studies
Ang II induces glomerular COX-2 expression and ac-
tivity. Infusion of Ang II for 5 days increased systolic
blood pressure (controls 130 ± 5 mm Hg vs. Ang II
170 ± 7 mm Hg) (P < 0.05) and resulted in significant
increases in the glomerular production of PGE2 (Fig. 1)
that was significantly inhibited by two different COX-2
inhibitors suggesting that increased COX-2 activity me-
diates in large part the glomerular production of PGE2
in response to Ang II. In separate experiments we also
determined the effect of COX-2 inhibition on the produc-
tion of PGE2 in glomeruli from control rats. COX-2 inhi-
bition did not inhibit the glomerular production of PGE2
suggesting that our glomerular preparation was devoid
of structures known to have high COX-2 expression such
as the macula densa [control 8.7 ± 0.8 ng/mg protein vs.
NS-398 (10−6 mol/L) 7.91 ± 1.2 ng/mg protein] (P = NS)
(N = 3). The nonspecific COX inhibitor indomethacin
also reduced the glomerular production of PGE2 to levels
slightly below those from control glomeruli but without
reaching statistical significance (Fig. 1).
In a separate group of rats we evaluated the effect
of the specific COX-2 inhibitor NS-398 administered
systemically on the glomerular production of PGE2 in
2146 Jaimes et al: Angiotensin II induces glomerular COX-2
200
COX-2
COX-1
*
*
150
100
50
0CO
X 
pr
ot
ei
n,
 O
D 
ar
bi
tra
ry
 u
ni
ts
Ang IIControl
Co
ntr
ol
An
g I
I
COX-1 COX-2 Actin COX-1/Actin COX-2/Actin
Control
(N = 6)
77.9 ± 6 29.4 ± 20 37.5 ± 0.2 2.1 ± 0.16 0.8 ± 05
Ang II
(N = 6)
106.2 ± 1.9 173.2 ± 45 37.6 ± 0.1 2.8 ± 0.06* 4.6 ± 1.2*
COX-2
COX-1
Actin
Fig. 2. Angiotensin II (Ang II) infusion in-
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protein expression and at a smaller degree
COX-1 as assessed by Western blot. Table in-
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Fig. 3. Angiotensin II (Ang II) infusion increases glomerular cyclooxygenase (COX-2) mRNA expression without significantly modifying COX-1
mRNA expression. Results are expressed as mean ± SEM (N = 3). ∗P < 0.05. GAPDH is glyeraldehyde-3-phosphate dehydrogenase; OD is optical
density.
rats infused with Ang II. Similar to our experiments
utilizing the ex vivo incubation with NS-398, the sys-
temic administration of NS-398 significantly reduced the
glomerular production of PGE2 (control 6.7 ± 0.7 ng/mg
PGE2, Ang II 10.7 ± 0.7 ng/mg PGE2, Ang II + NS-398
8.2 ± 1.4 ng/mg PGE2) (N = 6) (∗P < 0.05 vs. control and
Ang II + NS-398). Importantly, the systemic administra-
tion of NS-398 did significantly modify the increases in
blood pressure induced by Ang II (control 130 ± 5 mm
Hg, Ang II 168 ± 4 mm Hg, Ang II + NS-398 165 ± 1 mm
Hg) (∗P < 0.05 vs. control).
To determine whether these changes in COX-2 activ-
ity were the result of an increase in COX-2 protein ex-
pression, we measured COX-2 by Western blot in rats
infused with Ang II. As shown in Figure 2, Ang II in-
fusion significantly increased COX-2 protein expression
(5.7-fold COX-2/actin ratio compared to control) in the
glomerulus. These changes in COX-2 protein expres-
sion and activity were accompanied by a concomitant in-
crease in COX-2 mRNA expression suggesting that Ang
II increases COX-2 expression via transcriptional mecha-
nisms (Fig. 3). In addition, we determined whether Ang II
modified glomerular COX-1 protein and mRNA expres-
sion. As shown in Figure 2, Ang II infusion resulted in a
significant increase in COX-1 protein expression (1.3-fold
COX-1/actin ratio compared to control) that correlated
with an increase in glomerular COX-1 mRNA expression
(Fig. 3).
To determine the location of COX-2 in the glomeru-
lus where COX-2 is up-regulated, we performed
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immunohistochemistry studies in kidneys from control
and Ang II–infused rats. Positive stain for COX-2 was
clearly observed in the macula densas and thick ascend-
ing limb of both control as well as Ang II–infused rats
(Fig. 4A). In control rats no COX-2 was detected in the
glomerulus (Fig. 4B); however, in Ang II–infused rats
we observed glomeruli with positive stain for COX-2
localized mostly at the level of the glomerular epithe-
lium. (Fig. 4C). Given the critical role of the glomerular
mesangium in the pathogenesis of glomerular injury [27],
we performed dual labeling immunohistochemical stud-
ies to determine whether the glomerular mesangium ex-
presses COX-2 in vivo after Ang II infusion. We used
smooth muscle actin as a marker for the glomerular
mesangium. By using this method we were not able to
conclusively detect increases in mesangial COX-2 expres-
sion (not shown). In addition, we performed immuno-
histochemistry for COX-1 in controls as well as in rats
infused with Ang II. We observed COX-1 baseline ex-
pression in the glomeruli of control rats, but were unable
to appreciate any significant difference when compared
with Ang II–infused rats (not shown).
By in situ hybridization we clearly detected significant
increases in COX-2 mRNA expression in the glomerulus
of rats infused with Ang II suggesting that transcriptional
mechanisms are involved (Fig. 5).
In vitro studies
Ang II induces COX-2 expression and activity in mesan-
gial cells. To better explore the mechanisms by which
Ang II induces COX-2 expression and activity in the
glomerulus, we performed the following experiments in
cultured mesangial cells. Mesangial cells exposed to Ang
II (10−9 to 10−5 mol/L) for 24 hours significantly increased
PGE2 production in a dose-dependent manner (Fig. 6).
This increase in PGE2 production was blocked by the
AT1 receptor blocker irbesartan, suggesting that these
effects of Ang II on PGE2 production were mediated
through AT1 receptor activation (Fig. 7). In a similar man-
ner the Ang II–stimulated production of PGI2 was also
inhibited by AT1 receptor blockade (Fig. 7). In contrast,
Ang II did not significantly increase TxA2 production
(control 6.4 ± 0.3 ng/mg protein vs. Ang II 6.6 ± 0.2 ng/mg
protein) (N = 3) (P = NS) which support previous stud-
ies suggesting that cultured mesangial cells lack the iso-
merase that coverts PGH2 into TxA2 [30, 31]. Similar to
our findings in vivo, the specific COX-2 inhibitor NS-398
prevented the production of PGE2 and PGI2 in mesangial
cells stimulated with Ang II (Fig. 7). Furthermore, these
increases in COX-2 activity were accompanied by con-
comitant increases in COX-2 mRNA expression (Fig. 8).
In contrast, mesangial cell COX-1 mRNA expression was
not modified by Ang II stimulation (Fig. 8) and COX-1
Fig. 4. Angiotensin II (Ang II) increases the glomerular expression of
cyclooxygenase (COX-2). On basal conditions positive stain for COX-
2 was observed at the level of the macula densa (A, arrow) but no
significant COX-2 expression was observed in the glomerulus (A and
B). In the glomeruli from rats infused with Ang II, a significant number
of cells were found positive for COX-2 (C, arrows).
2148 Jaimes et al: Angiotensin II induces glomerular COX-2
A B
Fig. 5. Angiotensin II (Ang II) increases
glomerular cyclooxygenase (COX-2) mRNA
expression. On basal conditions no glomeru-
lar COX-2 mRNA expression was observed
(A). In glomeruli from Ang II–infused rats a
significant number of glomerular cells are pos-
itive for COX-2 mRNA expression (B).
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Fig. 6. Angiotensin II (Ang II) increased
prostaglandin E2 (PGE2) production in cul-
tured mesangial cells in dose-dependent man-
ner. Results are expressed as mean ± SEM
(N = 6). ∗P < 0.05 vs. control.
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Fig. 7. The angiotensin type 1 (AT1) recep-
tor blocker irbesartan (IRB) (10−6 mol/L)
and the cyclooxygenase (COX-2) inhibitor
NS-398 (10−7 mol/L) inhibit prostaglandin E2
(PGE2) and prostaglandin I2 (PGI2) produc-
tion in mesangial cells stimulated with an-
giotensin II (Ang II). Results are expressed
as mean ± SEM (N = 6). ∗P < 0.05 vs. all
other conditions; #P < 0.05 vs. control.
inhibition did not modify Ang II–stimulated PGE2 pro-
duction (not shown).
ROS mediate COX-2 induction by Ang II. We
have previously demonstrated that Ang II stimulates
NADH/NADPH oxidase activity in mesangial cells re-
sulting in the generation of ROS [11]. To investigate
whether NADH/NADPH oxidase–derived ROS partici-
pate in COX-2 induction by Ang II, mesangial cells were
exposed to DPI, a compound that by tightly binding to
flavoproteins is an effective inhibitor of flavin-containing
oxidases such as NADH/NADPH oxidase, (10−5 mol/L)
prior to Ang II. Treatment with DPI prevented the in-
crease in PGE2 and PGI2 production (Fig. 9), as well
as COX-2 mRNA expression (Fig. 8) increase in re-
sponse to Ang II, demonstrating that NADH/NADPH
oxidase–derived ROS are important intracellular signals
responsible for the initiation of COX-2 induction by
Ang II.
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Fig. 8. Cyclooxygenase (COX) mRNA ex-
pression in mesangial cells. Angiotensin II
(Ang II) (10−7 mol/L) (N = 3) increased
COX-2 mRNA expression that was prevented
by pretreatment with the nicotinamide ade-
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glyderaldehyde-3-phosphate dehydrogenase.
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Fig. 9. The reactive oxygen species (ROS)
scavenger Tiron, the nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase
inhibitor diphenyleneiodonium (DPI) as well
as catalase (CAT) inhibit mesangial cell pro-
duction of prostaglandin E2 (PGE2) and
prostaglandin I2 (PGI2) in response to an-
giotensin II (Ang II). Results are expressed as
mean ± SEM (N = 6). ∗P < 0.05 vs. control.
To more directly assess the role of ROS on COX-
2 induction, mesangial cells were treated with the cell-
permeable superoxide scavenger Tiron (5 × 10−3 mol/L)
prior to Ang II stimulation. Tiron prevented the increase
in PGE2 and PGI2 production by mesangial cells in re-
sponse to Ang II further suggesting that ROS are medi-
ators of COX-2 induction in response to Ang II (Fig. 9).
Superoxide anion produced as a result of increased
NADH/NADPH oxidase activity rapidly dismutates to
H2O2 spontaneously or via superoxide dismutase. As
shown in Figure 9, catalase, an enzyme that decomposes
H2O2, inhibited Ang II–stimulated PGE2 production,
suggesting that H2O2 is in fact the main ROS responsi-
ble for Ang II–stimulated PGE2 production. Similar find-
ings were observed when PGI2 production was measured
(Fig. 9).
MAPKs activation has been shown to participate in
COX-2 induction [32, 33]. We have previously demon-
strated that ROS produced as a result of Ang II stim-
ulation activate MAPK in mesangial cells [11]. Hence,
we treated mesangial cells with the specific MAPK-1 in-
hibitor PD98059 (50 lmol/L) prior to Ang II stimulation.
Pretreatment with PD98059 prevented Ang II induced
PGE2 (Ang II 4.22 ± 0.7 ng/mg vs. Ang II + PD98059
0.69 ± 0.2 ng/mg protein) (N = 6) (P < 0.05) and PGI2
production (Ang II 2.8 ± 0.2 ng/mg vs. 1.45 ± 0.1 ng/mg)
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Fig. 10. The cyclooxygenase (COX-2) in-
hibitors NS-398 (10−6 to 10−7 mol/L)
(N = 15), nimesulide (10−6 to 10−7 mol/L)
(N = 6) as well as indomethacin (Indo)
(10−5 mol/L) (N = 6), but not the COX-1
inhibitor SC-560 (10−7 mol/L) (N = 6) in-
hibit 3H-leucine incorporation in mesangial
cells stimulated with angiotensin II (Ang II)
(10−7 mol/L). Results are expressed as mean
± SEM. ∗P < 0.05 vs. Ang II.
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Fig. 11. The EP1 receptor blocker SC51322
significantly inhibited 3H-leucine incorpora-
tion in mesangial cells stimulated with an-
giotensin II (Ang II). Results are expressed
as mean ± SEM. ∗P < 0.05 vs. control.
(N = 6) (P < 0.05) demonstrating that MAPK activa-
tion is necessary for COX-2 induction by Ang II. Treat-
ment with PD98059 was not accompanied by increased
cell lethality as assessed by trypan blue exclusion (trypan
blue exclusion > 90%).
COX-2–derived prostaglandins mediate Ang II–
stimulated mesangial cell hypertrophy. To determine the
effect of prostaglandins produced in response to COX-
2 induction by Ang II on mesangial cell hypertrophy,
mesangial cells were exposed to Ang II (10−7 mol/L)
for 48 hours and mesangial cell hypertrophy measured
by 3H-leucine incorporation in the presence of the
COX-2 inhibitors NS-398 (10−7 to 10−6 mol/L), nime-
sulide (10−7 to 10−6 mol/L), the COX-1 inhibitor SC-
560 (10−7 mol/L) or the nonspecific COX inhibitor in-
domethacin (10−5 mol/L). As shown in Figure 10, Ang
II–induced mesangial cell hypertrophy was inhibited by
indomethacin as well as by the COX-2 inhibitors NS-
398 and nimesulide but not by the COX-1 inhibitor
SC-560 suggesting that prostaglandins originating from
COX-2–derived prostaglandins play an important role
in mediating the growth promoting effects of Ang II.
Higher concentrations of the COX-1 inhibitor were asso-
ciated with significant cell lethality. To determine whether
PGE2 was the prostaglandin responsible for the growth-
promoting effects of COX-2–derived prostaglandins,
mesangial cells were pretreated with the type 1 PGE2
receptor (EP1) blocker SC12311 (10−6 to 10−7 mol/L)
prior to Ang II (10−7 mol/L) stimulation. EP1 blockade
dose-dependently inhibited leucine incorporation in re-
sponse to Ang II demonstrating that PGE2 acting via the
EP1 receptor mediates the growth-promoting effects of
Ang II (Fig. 11).
DISCUSSION
In glomeruli isolated from rats infused with Ang II
for 5 days, PGE2 production was increased twofold and
was significantly inhibited by two different COX-2 in-
hibitors. The increase in glomerular PGE2 production
was accompanied by a concomitant 1.7-fold increase in
COX-2 mRNA and sixfold increase in protein expres-
sion suggesting that the effects of Ang II on COX-2 oc-
cur at a transcriptional level. In agreement with other
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studies we observed a higher glomerular baseline ex-
pression of COX-1 [34] compared to COX-2. COX-1 is
widely expressed in most cell types and although consti-
tutively expressed, its expression can be regulated [24].
In contrast, COX-2 is induced in response to a variety
of stimuli, including growth factors and cytokines such
as IL-1 and tumor necrosis factor-a (TNF-a) [7], fibrob-
last growth factor (FGF) [35], PDGF, and transform-
ing growth factor-b (TGF-b) [36]. Although COX-2 is
considered to be the COX-inducible isoform, there is
evidence for constitutive COX-2 expression in several
segments of the nephron, including the cortical macula
densa and the medullary interstitium [37]. Previous stud-
ies demonstrated that Ang II activates PLA2 and in-
duces the release of prostaglandins by mesangial cells
[38] and vascular smooth muscle cells [39, 40]. In the
current studies we demonstrate that COX-2 induction
is a major pathway by which Ang II induces the produc-
tion of prostaglandins in the glomerulus. Previous studies
have shown increased glomerular COX-2 expression and
activity in animal models of diabetes [41], ureteral ob-
struction [42], and renal insufficiency [37, 43] as well as
in humans with activated renin-angiotensin system due
to renal artery stenosis [44]. Importantly, in these con-
ditions the increase in COX-2 expression and activity is
not accompanied by changes in COX-1 activity [37, 41,
42, 44]. In our studies, we observed a small increase in
the glomerular expression of COX-1 after Ang II infu-
sion. Moreover, Ang II induces COX-2 expression and
activity in cultured vascular smooth muscle cells [45, 46]
as well as in human endothelial cells [47].
PGE2, the major prostanoid produced in the kidney,
has been shown to have either vasodilatory or vasocon-
strictive effects in the glomerular microcirculation de-
pending on binding to specific PGE2 receptors (EP). Four
distinct EP subtypes have been identified [48]. In the
glomerular microcirculation, EP4 is the most abundant
EP receptor and mediates PGE2-induced vasodilation,
while EP3 promotes vasoconstriction [8, 9]. In addition
to PGE2, other prostaglandins have significant hemo-
dynamic effects, including PGI2 which has a predomi-
nantly vasodilatory effect and TxA2 and PGF2a which are
vasoconstrictors [10]. Prostaglandins produced by COX-
2 in the glomerulus may have a critical role counterbal-
ancing the effects of Ang II upon vasoconstriction and
tubuloglomerular feedback. Recent studies suggest that
Ang II up-regulates COX-2 in the glomerular afferent
arteriole which is associated with increased TxA2 pro-
duction and increased constriction in response to va-
soactive agents [49]. These effects of COX-2–derived
prostaglandins may explain the deleterious effects of
acute COX inhibition on the glomerular microcircula-
tion when the renin-angiotensin system is activated. Our
studies indicate that Ang II induces COX-2 expression in
the glomerulus particularly at the level of the glomerular
epithelium. In the current studies we clearly demonstrate
that Ang II induces COX-2 mRNA and activity (PGE2
increased 200% and PGI2 increased 100%) in cultured
mesangial cells in a process that is dependent on both
ROS generation and MAPK activation.
In contrast, Ang II stimulation did not modify mesan-
gial cell COX-1 mRNA expression. We also demonstrate
that the ROS are derived from NADH/NADPH oxi-
dase and that H2O2 produced as a result of O2− dis-
mutation is the principal mediator. In support of this
notion, ROS scavengers have been shown to reduce TNF-
a–stimulated COX-2 mRNA and prostaglandin produc-
tion [7]. Our laboratory was the first to demonstrate in
mesangial cells that Ang II up-regulates NADH/NADPH
oxidase, stimulates the generation of O2− via PKC acti-
vation resulting in MAPK activation thereby promoting
mesangial cell hypertrophy and proliferation [11]. Al-
though we observed a rather strong increase in COX-2
expression in mesangial cells in vitro, we could not con-
clusively demonstrate increases in COX-2 expression in
the glomerular mesangium in vivo. These findings would
suggest that factors present under cell culture conditions
might favor strong COX-2 induction in mesangial cells in
response to Ang II, or alternatively, that the surround-
ing glomerular environment has a modulatory effect on
mesangial COX-2 expression [50, 51]. PGI2 has growth
inhibitory effects upon mesangial cells [20] and vascular
smooth muscle cells [52]. PGE2, on the other hand, has
been shown to either promote or to inhibit growth related
responses [15–18]. Our studies, show for the first time,
that COX-2 inhibition abolishes Ang II induced mesan-
gial cell hypertrophy, thereby supporting the notion that
prostaglandins produced as a result of COX-2 induction
are important mediators of the growth-promoting effects
of Ang II. Mesangial cells are known to express the EP1
and the EP4 receptors [53]. In our studies the EP1 recep-
tor blocker SC12111 prevented the growth-promoting ef-
fects of Ang II in mesangial cells suggesting that PGE2
via activation of the EP1 receptor mediates the growth
promoting effects of COX-2 in mesangial cells.
Our findings would suggest that COX-2 blockade
might be potentially beneficial in mitigating pathologic
glomerular growth related responses associated with ac-
tivation of the renin-angiotensin system and progressive
renal disease. However, recent studies have shown that
renal COX-2, but not COX-1, is involved in the pro-
duction of prostaglandins that antagonize the glomeru-
lar vasoconstrictor effects of Ang II [54]. Indeed, acute
selective and nonselective COX-2 inhibition results in
significant declines in glomerular filtration rate (GFR)
associated with blunting of the vasodilatory effects of
endogenous prostaglandins in the glomerular microcir-
culation [54]. Furthermore, with aging there is evidence
for increased COX-2 expression in the kidney suggest-
ing that in the elderly there may be a higher dependence
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on endogenous prostaglandins for maintaining a normal
GFR [55]. The complexity of effects of COX-2−derived
prostaglandins that result in a variety of hemodynamic
and nonhemodynamic actions suggests that novel strate-
gies are needed in order to selectively modulate the
actions of specific prostaglandins. Our studies support
the notion that targeting specific prostaglandin recep-
tors instead of blocking COX may be a suitable strat-
egy to modulate the pathologic effects of COX-2–derived
prostaglandins without negatively affecting glomerular
hemodynamics.
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